Authors:
Ivy Nwogu, PharmD
Megan Supple, PharmD, BCACP, CPP

Reviewers:
Snehal H. Bhatt, PharmD, BCPS, BCCP
Stuart T. Haines, PharmD, BCPS, BCACP

Citation: Jones S, Mulder H, Wruck L, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 May 27;384(21):1981-1990.

The Problem

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death and disability in the United States, accounting for 32% of all global deaths.1,2 Among individuals with ASCVD, aspirin has been the cornerstone of antithrombotic therapy and current guidelines strongly recommend its use for secondary prevention of cardiovascular events.3 However, there is no consensus regarding the preferred dosage of aspirin in patients with ASCVD, which has led to variability in prescribing patterns. This is likely due to the lack of head-to-head trials evaluating different aspirin doses and data weighing the clinical benefits and adverse effects experienced with aspirin. Therefore, the question remains; which dose of aspirin is the safest and most effective in patients with established ASCVD?

This content has been restricted to logged-in users only. Please login to view this content.